Resiquimod (R-848)

For research use only.

Catalog No.S8133 Synonyms: S28463

8 publications

Resiquimod (R-848) Chemical Structure

CAS No. 144875-48-9

Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.

Selleck's Resiquimod (R-848) has been cited by 8 publications

Purity & Quality Control

Choose Selective TLR Inhibitors

Biological Activity

Description Resiquimod (R-848, S28463) is an immune response modifier that acts as a potent TLR 7/TLR 8 agonist that induces the upregulation of cytokines such as TNF-α, IL-6 and IFN-α. Resiquimod reduces hepatitis C virus (HCV) infection. Phase 2.
Targets
TLR7 [1] TLR8 [1]
In vitro

Resiquimod activates immune cells and induces proliferation of wild-type splenocytes via the Toll-like receptor 7 (TLR7)-MyD88-dependent signaling pathway. [1] Resiquimod also modulates dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. [2] Resiquimod induces the differentiation of myeloid-derived suppressor cells into macrophages and dendritic cells, and may improve cancer immunotherapy by reducing immunosuppressive MDSCs. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
PBMC M3zFOmZ2dmO2aX;uJIF{e2G7 MWCzNEBvVQ>? NWG1NIhOOThiaILz M1m2dWlv\HWldHnvckBw\iC2eYDlJFEhUU[QIIPlZ5JmfGmxbjDpckBpfW2jbjDQRm1EKGG2IEOwJI5OKGGodHXyJFE5KGi{czDifUBGVEmVQTygRYN1cX[rdIm9NE4xODF{Nd88UU4> MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ|MkiyOEc,OjB{M{K4NlQ9N2F-
PBMC NWfW[ZVDTnWwY4Tpc44h[XO|YYm= NVv4UXVtOTBibl2= NVX4fYtPOThiaILz M3LhNWlv\HWldHnvckBw\iC2eYDlJFEhUU[QIIPlZ5JmfGmxbjDpckBpfW2jbjDQRm1EKGG2IEGwJI5OKGGodHXyJFE5KGi{czDifUBGVEmVQTygRYN1cX[rdIm8NE4xODF{Nd88UU4> NWj2b2pKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyN|I5OjRpPkKwNlMzQDJ2PD;hQi=>
PBMC MmPtSpVv[3Srb36gZZN{[Xl? M4DSdFExOCCwTR?= NWjqdFVLOThiaILz NGrC[2pKdmS3Y4Tpc44hd2ZidInw[UAyKEmITjDz[YNz\XSrb36gbY4hcHWvYX6gVGJOSyCjdDCxNFAhdk1iYX\0[ZIhOThiaILzJIJ6KEWOSWPBMEBC[3Srdnn0fV0xNjByNU[x{txONg>? MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODJ|MkiyOEc,OjB{M{K4NlQ9N2F-
PBMC NIXUfYNHfW6ldHnvckBie3OjeR?= M{ewelMxOCCwTR?= NV:3bpYzOThiaILz NUjWV3JUUW6mdXP0bY9vKG:oIIT5dIUhOSCLRl6gd4VkemW2aX;uJIlvKGi3bXHuJHBDVUNiYYSgN|AxKG6PIHHmeIVzKDF6IHjyd{BjgSCHTFnTRUwhSWO2aY\peJk:OC5yMEeyOu69VS5? Mn\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB{M{K4NlQoRjJyMkOyPFI1RC:jPh?=
PBMC MUfGeY5kfGmxbjDhd5NigQ>? NUTYSmNmOTByMDDuUS=> Ml3KNVghcHK| MlTMTY5lfWO2aX;uJI9nKHS7cHWgNUBKTk5ic3XjdoV1cW:wIHnuJIh2dWGwIGDCUWMh[XRiMUCwNEBvVSCjZoTldkAyQCCqcoOgZpkhTUyLU1GsJGFkfGm4aYT5QVAvODB5N{ZOwG0v M4\MVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMkOyPFI1Lz5{MEKzNlgzPDxxYU6=
Huh7 MXLBcpRqfmm{YXygZZN{[Xl? NXe2S2RJPDhiaILz NH3FfGRCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJS1ZiaX7m[YN1\WRiaIXtZY4hUHWqNzDy[ZBtcWOxbjDj[YxteyC2cnXheIVlKG[xcjC0PEBpenNid3n0bEBlenWpLXnu[JVk\WRibXn4[YQh\G:wb4KgbJVu[W5iUFLNR{B{fXCncn7heIFvfHNiYYPz[ZN{\WRiYYOgeolz[WxibHX2[Yx{KGK7IHz1Z4ln\XKjc3WgZZN{[XluIFXDOVA:OC5yMkVOwG0v NWPHcmJVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OFg1QTdpPkG3OVQ5PDl5PD;hQi=>
Huh7 MYHBcpRqfmm{YXygZZN{[Xl? MXm0PEBpenN? NH;xSJJCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJS1ZiaX7m[YN1\WRiaIXtZY4hUHWqNzDy[ZBtcWOxbjDj[YxteyC2cnXheIVlKG[xcjC0PEBpenNid3n0bEBlenWpLXnu[JVk\WRic3nu[4xmKGSxbn;yJIh2dWGwIGDCUWMhe3WyZYLuZZRidnS|IHHzd4V{e2WmIHHzJJZqemGuIHzleoVteyCkeTDseYNq\mW{YYPlJIF{e2G7LDDFR|UxRTBwMEK2Oe69VS5? M3SxPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
PBMC NYTTT5hbTnWwY4Tpc44h[XO|YYm= MmPRNlQhcHK| M360NWlv\HWldHnvckBw\iCLRl7hcJBp[TKjIHzleoVtKGmwIHj1cYFvKFCETVOgZZN{\XO|ZXSgZZMh\HK3ZzDs[ZZmdCClYYXzbY5oKG2jeHntZYwh[3m2b3vpcoUhcW6mdXP0bY9vKGGodHXyJFI1KGi{czDy[YxifGm4ZTD0c{Bkd262cn;sMEBC[3Srdnn0fV0xNjIQvF2u NWXw[mpqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OFg1QTdpPkG3OVQ5PDl5PD;hQi=>
PBMC MWfGeY5kfGmxbjDhd5NigQ>? M4\IZVI1KGi{cx?= MnLhWI95cWNiaX7keYN1cW:wIH;mJGlNOS2kZYThJIxmfmWuIHnuJIh2dWGwIGDCUWMh[XO|ZYPz[YQh[XNiZIL1[{Bt\X[nbDDjZZV{cW6pIH3hfIlu[WxiY4n0c4tqdmViaX7keYN1cW:wIHHmeIVzKDJ2IHjyd{Bz\WyjdHn2[UB1dyClb370do9tNCCDY4Tpeol1gT1zzszNMi=> NH;ZTYo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W0PFQ6Pyd-MUe1OFg1QTd:L3G+
PBMC MnXzSpVv[3Srb36gZZN{[Xl? MnnPNlQhcHK| NHTRUJhVd3irYzDpcoR2[3Srb36gc4YhUUx4IHzleoVtKGmwIHj1cYFvKFCETVOgZZN{\XO|ZXSgZZMh\HK3ZzDs[ZZmdCClYYXzbY5oKG2jeHntZYwh[3m2b3vpcoUhcW6mdXP0bY9vKGGodHXyJFI1KGi{czDy[YxifGm4ZTD0c{Bkd262cn;sMEBC[3Srdnn0fV0y|ryPLh?= MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV2OES5O{c,OTd3NEi0PVc9N2F-
PBMC M3y2NWZ2dmO2aX;uJIF{e2G7 NIPhOVgzPCCqcoO= NXS4e25jXG:6aXOgbY5lfWO2aX;uJI9nKFSQRnHsdIhiKGyndnXsJIlvKGi3bXHuJHBDVUNiYYPz[ZN{\WRiYYOg[JJ2\yCuZY\lcEBk[XW|aX7nJI1igGmvYXygZ5l1d2urbnWgbY5lfWO2aX;uJIFnfGW{IEK0JIhzeyC{ZXzheIl3\SC2bzDjc451em:uLDDBZ5Rqfmm2eU2x{txONg>? NVLZZVl4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OFg1QTdpPkG3OVQ5PDl5PD;hQi=>
HEK293 MWnGeY5kfGmxbjDhd5NigQ>? MXG2JIhzew>? NEjzPFNC\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHRNWjdiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkA3KGi{czDifUBPTmujcIDhRk1tfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIF3FR|0xNjIQvF2u M4PzUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUSzOFI2Lz5|MEG0N|QzPTxxYU6=
HEK293 MlyxSpVv[3Srb36gZZN{[Xl? MXHB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTMVlch\XiycnXzd4VlKGmwIFjFT|I6OyClZXzsd{Bkd2W6cILld5NqdmdicF7pSpR6Oi2VRVHQJJJmeG:{dHXyJIJ6KHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVA:OC5{NkCx{txONg>? NWHmZYVxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyN|I5OjRpPkKwNlMzQDJ2PD;hQi=>
HEK293 M2HL[WZ2dmO2aX;uJIF{e2G7 NXHndnpvPiCqcoO= M2HC[2Fod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGxTQCCneIDy[ZN{\WRiaX6gTGVMOjl|IHPlcIx{KGGodHXyJFYhcHK|IHL5JG5Hc2GycHHCMYx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSxiTVXDQVAvO87:TT6= M13jRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUSzOFI2Lz5|MEG0N|QzPTxxYU6=
HEK M2HBPWZ2dmO2aX;uJIF{e2G7 NEXM[ZA5KHSxIEGyJIhzew>? NIPBR21C\2:waYP0JIFkfGm4aYT5JIF1KGi3bXHuJHRNWjdiZYjwdoV{e2WmIHnuJGhGUyClZXzsd{Bi\nSncjC4JJRwKDF{IHjyd{BjgSCQRnvhdJBiSi:VRVHQJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NU4{PM7:TT6= NXuxdJAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxOVIxPDZpPkK5NVUzODR4PD;hQi=>
HEK NID5e3BHfW6ldHnvckBie3OjeR?= MkjLNlQhcHK| MY\B[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTMVlchfHKjboPm[YN1\WRiaX6gTGVMKGOnbHzzJIF{e2W|c3XkJIF{KE6Ia3HwdIFDKGmwZIXjeIlwdiCjZoTldkAzPCCqcoOgZpkhe3CnY3nmbYMhe2WlcnX0[YQh[WytYXzpcoUheGixc4DoZZRie2ViZ3Xu[UBie3OjeTygSWM2OD1zLkVOwG0v NYr2VZprRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK4N|c5OTFpPkKyPFM4QDFzPD;hQi=>
HEK293 NGPldHlHfW6ldHnvckBie3OjeR?= MnzJNlQhcHK| NXjveo9nSWexbnnzeEBi[3Srdnn0fUBifCCqdX3hckBVVFJvNzDlfJBz\XO|ZXSgbY4hUEWNMkmzJINmdGy|IHHmeIVzKDJ2IHjyd{BjgSCVRVHQJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9NU42|ryPLh?= NIq1UJA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEO4N|Q4PSd-MkSzPFM1PzV:L3G+
HEK293 NVfTUJRSTnWwY4Tpc44h[XO|YYm= M1mxd|YhcHK| MnrhRYdwdmm|dDDhZ5Rqfmm2eTDheEBpfW2jbjDUUHI5KGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMhcW6ldXLheIVlKG[xcjC2JIhzeyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZktKEWFNUC9OO69VS5? NWq3WmlGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyO|AxOjlpPkK3NlcxODJ7PD;hQi=>
HEK293 NULHd2pjTnWwY4Tpc44h[XO|YYm= NFPUPWIzPCCqcoO= MWLB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTMVk05KGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JHNGSVBicnXwc5J1\XJiZ3Xu[UBie3OjeTygSWM2OD12LkZOwG0v MkPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR|OEO0O|UoRjJ2M{izOFc2RC:jPh?=
HEK NWH0VnNSTnWwY4Tpc44h[XO|YYm= Mn\QPEB1dyBzMjDodpM> MVnB[49vcXO2IHHjeIl3cXS7IHH0JIh2dWGwIGTMVlgh\XiycnXzd4VlKGmwIFjFT{Bk\WyuczDh[pRmeiB6IITvJFEzKGi{czDifUBPTmujcIDhRk9UTUGSIILldI9zfGW{IHflcoUh[XO|YYmsJGVEPTB;Nj6xN:69VS5? NIDyRmM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUG1NlA1Pid-MkmxOVIxPDZ:L3G+
HEK M2no[GZ2dmO2aX;uJIF{e2G7 MYGyOEBpenN? M1\BTmFod26rc4SgZYN1cX[rdImgZZQhcHWvYX6gWGxTQCC2cnHud4Zm[3SnZDDpckBJTUtiY3XscJMh[XO|ZYPz[YQh[XNiTl\rZZBx[UJiaX7keYN1cW:wIHHmeIVzKDJ2IHjyd{BjgSC|cHXjbYZq[yC|ZXPy[ZRm\CCjbHvhcIlv\SCyaH;zdIhifGG|ZTDn[Y5mKGG|c3H5MEBGSzVyPU[uOO69VS5? NHG3Z2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkizO|gyOSd-MkK4N|c5OTF:L3G+
PBMC MmjTSpVv[3Srb36gZZN{[Xl? NYnZcXN4OjRiaILz M4njV2lv[3KnYYPlJIlvKEmITnHsdIhiKGyndnXsJIlvKGi3bXHuJHBDVUNiYX\0[ZIhOjRiaILzJJJmdGG2aY\lJJRwKGOxboTyc4w> NGixfGo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{W0PFQ6Pyd-MUe1OFg1QTd:L3G+
PBMC NVTFNpFZTnWwY4Tpc44h[XO|YYm= M3XQVFI1KGi{cx?= NFrGOYVKdmO{ZXHz[UBqdiB{Jzy1K{1wdGmpb3Hk[Y56dGG2ZTDzfY51cGG|ZTDs[ZZmdCCrbjDoeY1idiCSQl3DJIFnfGW{IEK0JIhzeyC{ZXzheIl3\SC2bzDjc451em:u M4\aO|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
PBMC MWfUc5hq[2m2eTDhd5NigQ>? MViyOEBpenN? NWXDPW57XG:6aXPpeJkh[XO|ZYPz[YQh[XNiaX7jdoVie2ViaX6gTWw3KGyndnXsJIlvKGi3bXHuJHBDVUNiYX\0[ZIhOjRiaILzJJJmdGG2aY\lJJRwKGOxboTyc4w> M17JW|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5NUS4OFk4Lz5zN{W0PFQ6PzxxYU6=
Huh7 M3vrdmFvfGm4aYLhcEBie3OjeR?= Mn3YNlQhcHK| M{H2NGFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhEXiCrbn\lZ5Rm\CCqdX3hckBJfWh5IILldIxq[2:wIHPlcIx{KHS{ZXH0[YQh\m:{IEK0JIhzeyC5aYToJIRzfWdvaX7keYNm\CCqdX3hckBRSk2FIIP1dIVzdmG2YX70d{Bie3Onc4Pl[EBieyC4aYLhcEBt\X[nbIOgZpkhdHWlaX\ldoF{\SCjc4PhfS=> NXSyXpNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe1OFg1QTdpPkG3OVQ5PDl5PD;hQi=>
Huh7 NX7wTotxSW62aY\pdoFtKGG|c3H5 MV\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDIR3YhcW6oZXP0[YQhcHWvYX6gTJVpPyC{ZYDsbYNwdiClZXzsd{B1emWjdHXkJJdqfGhiZIL1[{1qdmS3Y3XkJIh2dWGwIGDCUWMhe3WyZYLuZZRidnS|IHHzd4V{e2WmIHHzJJZqemGuIHzleoVteyCkeTDseYNq\mW{YYPlJIF{e2G7 MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzV2OES5O{c,OTd3NEi0PVc9N2F-
PBMC NGTSfo1HfW6ldHnvckBie3OjeR?= NHzLW|IzOi53IIXN NIDnfZIzPCCqcoO= NET1boVC\2:waYP0JIFkfGm4aYT5JIF1KFSOUkevWGxTQCCrbjDoeY1idiCSQl3DJIF{e2W|c3XkJIF{KGmwZIXjeIlwdiCxZjDUUmYu[WyyaHGgdJJw\HWldHnvckBifCB{Mj61JJVOKGGodHXyJFI1KGi{czDifUBndG:5IHP5eI9u\XS{aXOgZY5idHm|aYO= NWHtOo44RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSzPFM1PzVpPkK0N|g{PDd3PD;hQi=>
PBMC M2e2TmludXWwb33v[JVt[XSxcomgZZN{[Xl? Mn\XNVYhfU1? MlTyNlQhcHK| MU\JcY12dm:vb3T1cIF1d3K7IHHjeIl3cXS7IHnuJIh2dWGwIGDCUWMh[XO|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGlNNTZic3XjdoV1cW:wIHH0JFE3KHWPIHHmeIVzKDJ2IHjyd{BjgSCHTFnTRS=> NFG3clg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEK1OFQ5PCd-MkiyOVQ1QDR:L3G+
BMD NUjhdXFPTnWwY4Tpc44h[XO|YYm= MlTCNUB2VQ>? NIXqUlM1QCCqcoO= NXfDOGNlUW6mdXP0bY9vKG:oIGTMVlchemWlZYD0c5IudWWmaXH0[YQhSzV5QlyvOkBud3W|ZTDCUWQh[2WubIOgZYN1cX[jdHnvckBie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YhS0R6NjDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCobH;3JIN6fG:vZYTyfS=> M2nGUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mkm5NVI3Lz5zOUK5PVEzPjxxYU6=
BMD NYW0eG5QTnWwY4Tpc44h[XO|YYm= MUexJJVO NE\DOJk1QCCqcoO= MYDJcoR2[3Srb36gc4YhXEyUNzDy[YNmeHSxcj3t[YRq[XSnZDDDOVdDVC94IH3veZNmKEKPRDDj[YxteyCjY4TpeoF1cW:wIHHzd4V{e2WmIHHzJJVxemWpdXzheIlwdiCxZjDNTGMh[2yjc4OtNkBifCBzIIXNJIFnfGW{IES4JIhzeyCkeTDmcI94KGO7dH;t[ZRzgQ>? M4LTTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7Mkm5NVI3Lz5zOUK5PVEzPjxxYU6=
BMD NHjRZ|JHfW6ldHnvckBie3OjeR?= MkLGNUB2VQ>? MVe0PEBpenN? NUGzc29yUW6mdXP0bY9vKG:oIGTMVlchemWlZYD0c5IudWWmaXH0[YQhSzV5QlyvOkBud3W|ZTDCUWQh[2WubIOgZYN1cX[jdHnvckBie3Onc4Pl[EBieyC3cILl[5Vt[XSrb36gc4YhS0R2MDDheEAyKHWPIHHmeIVzKDR6IHjyd{BjgSCobH;3JIN6fG:vZYTyfS=> NFHIeo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK5PVEzPid-MUmyPVkyOjZ:L3G+
BMD MVHGeY5kfGmxbjDhd5NigQ>? MnzaOUB2VQ>? MlrsNlQhcHK| NETDeGlKdmS3Y4Tpc44hd2ZiVFzSO{Bz\WOncITvdk1u\WSrYYTl[EBEPTeETD:2JI1wfXOnIFLNSEBk\WyuczDhZ5RqfmG2aX;uJIF{e2W|c3XkJIF{KEmOMUKgdJJw\HWldHnvckBifCB3IIXNJIFnfGW{IEK0JIhzeyCkeTDFUGlUSQ>? MmHvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{OUmxNlYoRjF7Mkm5NVI3RC:jPh?=

... Click to View More Cell Line Experimental Data

In vivo In wild-type mice, Resiquimod (50 nmol, i.p.) induces increased serum concentrations of IFN-alpha, TNF-alpha and IL-12, while neither TLR7-deficient mice nor MyD88-deficient mice show an increase in these cytokines. [1] In a murine model of allergic asthma, Resiquimod (i.n., 20 μg/mouse) reduces allergen induced airway reactivity and inflammation via reduction in Nrf2 signaling. [4]

Protocol

Animal Research:

[1]

- Collapse
  • Animal Models: Wild-type mice, TLR7-deficient mice, and MyD88-deficient mice
  • Dosages: 50 nmol
  • Administration: i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 63 mg/mL (200.39 mM)
Water Insoluble
Ethanol '''''21 mg/mL warmed

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 314.38
Formula

C17H22N4O2

CAS No. 144875-48-9
Storage powder
in solvent
Synonyms S28463
Smiles CCOCC1=NC2=C(N1CC(C)(C)O)C3=CC=CC=C3N=C2N

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04127864 Active not recruiting Procedure: Colorectal cancer surgery Colorectal Cancer|Surgery University of Copenhagen|Zealand University Hospital October 14 2019 --
NCT02688478 Unknown status Other: Phthalate|Other: Filtered Air|Other: Allergen Allergies University of British Columbia February 2 2017 Not Applicable
NCT00960752 Completed Drug: gp100|Drug: R848 gel|Drug: MAGE-3 Melanoma M.D. Anderson Cancer Center May 20 2010 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
Tags: buy Resiquimod (R-848) | Resiquimod (R-848) supplier | purchase Resiquimod (R-848) | Resiquimod (R-848) cost | Resiquimod (R-848) manufacturer | order Resiquimod (R-848) | Resiquimod (R-848) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID